Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00003437
Status:
UNKNOWN
Last Update Posted:
2013-12-04
First Post:
1999-11-01
Brief Title:
Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
Sponsor:
Medical Research Council
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Medical Research Council Working Party on Leukaemia in Children UK National Lymphoblastic Leukaemia ALL Trial
Status:
UNKNOWN
Status Verified Date:
2003-02
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Hormone therapy may stop the growth of cancer cells Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die Combining hormone therapy with chemotherapy may kill more cancer cells It is not yet known which hormone therapy and chemotherapy regimen is most effective for acute lymphoblastic leukemia
PURPOSE Randomized phase III trial to compare the effectiveness of different steroid therapy and chemotherapy regimens in treating children who have acute lymphoblastic leukemia
PURPOSE Randomized phase III trial to compare the effectiveness of different steroid therapy and chemotherapy regimens in treating children who have acute lymphoblastic leukemia
Detailed Description:
OBJECTIVES
Compare the effects of oral prednisolone vs oral dexamethasone on remission rate event-free survival and overall survival of children with acute lymphoblastic leukemia
Compare the effect of oral mercaptopurine MP vs oral thioguanine TG on remission rate event-free survival and overall survival of this patient population
Assess the effect of a schedule concentrating on tight control of maintenance therapy compensating where necessary for constitutional drug resistance and avoiding poor physician or patient compliance on event-free survival of these patients
Compare the pharmacokinetics of MP and TG in these patients
Collect data on the presence or absence of minimal residual disease in serial bone marrow samples to assess its clinical importance
OUTLINE This is a randomized multicenter study Patients are randomized twice during the study prednisolone vs dexamethasone and mercaptopurine vs thioguanine Patients are initially stratified according to risk status standard vs intermediate vs high Patients are stratified at the second randomization according to gender age under 2 years vs 2 to 9 years vs over 9 years WBC under 50000mm3 vs over 50000mm3 steroid allocation and early response slow vs rapid
Patients with verified CNS disease receive weekly intrathecal IT methotrexate until 2 consecutive clear cerebrospinal fluid samples have been obtained Cranial radiotherapy is administered over 15-21 days during weeks 5-8 concurrently with methotrexate IT in the appropriate regimen Following radiotherapy these patients receive monthly methotrexate IT for 1 year and then every 3 months until the end of therapy
Patients with testicular infiltration receive additional radiation fractions daily for 12 days to both testes during weeks 5-8
Regimen A standard-risk patients
Remission induction Patients receive the assigned oral steroid prednisolone or dexamethasone twice a day on days 1-28 vincristine IV on days 1 8 15 and 22 and asparaginase IM three days a week for 9 doses beginning on day 4 Patients also receive cytarabine IT on day 1 and methotrexate IT on day 8
If bone marrow is M3 at day 15 or M2 at day 29 therapy continues on regimen C Otherwise patient continues on regimen A
Consolidation Patients taper the assigned steroid over days 29-35 plus receive vincristine IV on day 29 and methotrexate IT on days 29 36 43 and 50 Patients also receive oral thiopurine mercaptopurine or thioguanine on days 29-56
Interim maintenance I Patients receive the assigned oral steroid twice a day on days 57-61 and 85-89 plus vincristine IV on days 57 and 85 Patients also receive the assigned oral thiopurine on days 57-105 and oral methotrexate on days 57 64 71 78 85 92 99 and 106
Delayed intensification I Patients receive oral dexamethasone twice a day on days 113-119 and 127-133 plus vincristine IV and daunorubicin IV over 6 hours on days 113 120 and 127 Patients also receive asparaginase IM three days a week for 6 doses beginning on day 114 or 115 and methotrexate IT on day 113 Cyclophosphamide IV over 30 minutes is administered on day 141 Patients also receive oral thioguanine on days 141-154 cytarabine IV or subcutaneously SC twice a day on days 142-145 and 149-152 and methotrexate IT on days 141 and 148
Interim maintenance II Patients receive the assigned oral steroid twice a day on days 162-166 and 190-194 and vincristine IV on days 162 and 190 Patients also receive the assigned oral thiopurine on days 162-210 and oral methotrexate on days 162 169 176 183 190 197 204 and 211
Delayed intensification II Patients receive oral dexamethasone on days 218-224 and 239-245 vincristine IV and doxorubicin IV over 6 hours on days 218 225 and 232 and methotrexate IT on day 218 Asparaginase IM is administered three days a week for 6 doses beginning on day 219 or 220 Patients then receive cyclophosphamide IV over 30 minutes on day 246 oral thioguanine on days 246-259 cytarabine IV or SC on days 247-250 and 254-257 and methotrexate IT on days 246 and 253
Maintenance Treatment is given as a 12-week course for 6 courses girls or 11 courses boys Patients receive the assigned oral steroid twice a day on days 1-5 29-33 and 57-61 of each course vincristine IV on days 1 29 and 57 of each course and the assigned oral thiopurine daily during each course Methotrexate IT is administered to girls on day 1 of each course and on day 84 of course 6 while boys receive 1 dose on day 1 of course 11 Patients also receive oral methotrexate on days 8 15 22 29 36 43 50 57 64 71 and 78 of each course
Regimen B intermediate-risk patients
Remission induction Patients receive the assigned oral steroid vincristine and asparaginase as in regimen A remission induction Patients also receive daunorubicin IV over 6 hours on days 1 8 15 and 22 cytarabine IT on day 1 and methotrexate IT on day 8
If bone marrow is M3 at day 8 or M2 at day 29 therapy continues on regimen C Otherwise patient continues on regimen B
Consolidation The assigned steroid is tapered over days 29-35 Patients also receive cyclophosphamide IV over 30 minutes on days 29 and 43 cytarabine IV or SC on days 30-33 37-40 44-47 and 51-54 oral mercaptopurine on days 29-56 and methotrexate IT on days 29 36 43 and 50
Patients with M1 or M2 bone marrow on day 64 proceed to interim maintenance I
Interim maintenance I Patients receive the assigned steroid vincristine the assigned thiopurine and oral methotrexate as in regimen A Patients also receive methotrexate IT on days 64 and 92
Delayed intensification I Patients receive oral dexamethasone on days 120-126 and 134-140 plus vincristine IV and doxorubicin IV over 6 hours on days 120 127 and 134 Patients also receive asparaginase IM three days a week for 6 doses beginning on day 121 or 122 and methotrexate IT on day 120 Patients then receive cyclophosphamide IV over 30 minutes on day 148 oral thioguanine on days 148-161 cytarabine IV or SC on days 149-152 and 156-159 and methotrexate IT on days 148 and 155
Interim maintenance II Patients receive the assigned oral steroid twice a day on days 169-173 and 197-201 vincristine IV on days 169 and 197 the assigned oral thiopurine on days 169-217 oral methotrexate on days 176 183 190 197 204 and 211 and methotrexate IT on days 169 and 197
Delayed intensification II Patients receive oral dexamethasone on days 225-231 and 239-245 vincristine IV and doxorubicin IV over 6 hours on days 225 232 and 239 and methotrexate IT on day 225 Asparaginase IM is administered three days a week for 6 doses beginning on day 226 or 227 Patients then receive cyclophosphamide IV over 30 minutes on day 253 oral thioguanine on days 253-266 cytarabine IV or SC on days 253-256 and 260-263 and methotrexate IT on days 253 and 260
Maintenance Treatment is administered as in regimen A
Regimen C Slow early response to regimen A or B OR high-risk patients
Remission induction for patients switching from regimen A Patients continue assigned oral steroid for a total of 35 days Patients also receive vincristine IV on days 15 22 and 29 and daunorubicin IV over 6 hours on days 15 and 22 Asparaginase IM is administered 3 days a week for 6 doses Patients receive methotrexate IT on day 29 patients with CNS disease also receive doses on days 15 and 22
Remission induction for patients switching from regimen B Patients continue assigned oral steroid for a total of 35 days Patients also receive vincristine IV and daunorubicin IV over 6 hours on days 8 15 and 22 Asparaginase IM continues three days a week for up to 6 doses Patients also receive methotrexate IT on day 29 patients with CNS disease also receive doses on days 14 and 21
Consolidation Patients receive cyclophosphamide IV over 30 minutes on days 36 and 64 cytarabine IV or SC on days 37-40 44-47 65-68 and 72-75 oral mercaptopurine on days 36-49 and 64-77 vincristine IV on days 50 57 78 and 85 pegaspargase IM on days 50 and 78 and methotrexate IT on days 36 43 50 and 57
Interim maintenance I Patients receive vincristine IV and methotrexate IV on days 99 109 119 129 and 139 Pegaspargase IM is administered on days 100 and 110 and methotrexate IT is administered on days 99 and 129 patients with CNS disease do not receive the dose on day 129
Patients with M1 or M2 bone marrow proceed to delayed intensification I
Delayed intensification I
Reinduction Patients receive vincristine IV and doxorubicin IV over 6 hours on days 162 169 and 176 oral dexamethasone twice a day on days 162-168 and 176-82 methotrexate IT on day 162 and pegaspargase IM on day 165
Reconsolidation Patients receive cyclophosphamide IV over 30 minutes on day 190 oral thioguanine on days 190-203 cytarabine IV or SC on days 191-194 and 197-200 vincristine IV on days 204 and 211 and pegaspargase IM on day 204 Methotrexate IT is administered on days 190 and 197 patients with CNS disease do not receive the dose on day 197
Interim maintenance II Patients receive vincristine IV and methotrexate IV on days 218 228 238 248 and 258 Pegaspargase IM is administered on days 219 and 239 Patients also receive methotrexate IT on days 218 and 248 patients with CNS disease do not receive the dose on day 248
Delayed intensification II
Reinduction Patients receive vincristine IV and doxorubicin IV over 6 hours on days 274 281 and 288 oral dexamethasone twice a day on days 274-280 and 288-294 methotrexate IT on day 274 and pegaspargase IM on day 277
Reconsolidation Patients receive cyclophosphamide IV over 30 minutes on day 302 oral thioguanine on days 302-315 cytarabine IV or SC on days 303-306 and 309-312 and vincristine IV on days 316 and 323
Maintenance Treatment is administered as in regimen A
PROJECTED ACCRUAL Approximately 1800 patients will be accrued for this study within 6 years
Compare the effects of oral prednisolone vs oral dexamethasone on remission rate event-free survival and overall survival of children with acute lymphoblastic leukemia
Compare the effect of oral mercaptopurine MP vs oral thioguanine TG on remission rate event-free survival and overall survival of this patient population
Assess the effect of a schedule concentrating on tight control of maintenance therapy compensating where necessary for constitutional drug resistance and avoiding poor physician or patient compliance on event-free survival of these patients
Compare the pharmacokinetics of MP and TG in these patients
Collect data on the presence or absence of minimal residual disease in serial bone marrow samples to assess its clinical importance
OUTLINE This is a randomized multicenter study Patients are randomized twice during the study prednisolone vs dexamethasone and mercaptopurine vs thioguanine Patients are initially stratified according to risk status standard vs intermediate vs high Patients are stratified at the second randomization according to gender age under 2 years vs 2 to 9 years vs over 9 years WBC under 50000mm3 vs over 50000mm3 steroid allocation and early response slow vs rapid
Patients with verified CNS disease receive weekly intrathecal IT methotrexate until 2 consecutive clear cerebrospinal fluid samples have been obtained Cranial radiotherapy is administered over 15-21 days during weeks 5-8 concurrently with methotrexate IT in the appropriate regimen Following radiotherapy these patients receive monthly methotrexate IT for 1 year and then every 3 months until the end of therapy
Patients with testicular infiltration receive additional radiation fractions daily for 12 days to both testes during weeks 5-8
Regimen A standard-risk patients
Remission induction Patients receive the assigned oral steroid prednisolone or dexamethasone twice a day on days 1-28 vincristine IV on days 1 8 15 and 22 and asparaginase IM three days a week for 9 doses beginning on day 4 Patients also receive cytarabine IT on day 1 and methotrexate IT on day 8
If bone marrow is M3 at day 15 or M2 at day 29 therapy continues on regimen C Otherwise patient continues on regimen A
Consolidation Patients taper the assigned steroid over days 29-35 plus receive vincristine IV on day 29 and methotrexate IT on days 29 36 43 and 50 Patients also receive oral thiopurine mercaptopurine or thioguanine on days 29-56
Interim maintenance I Patients receive the assigned oral steroid twice a day on days 57-61 and 85-89 plus vincristine IV on days 57 and 85 Patients also receive the assigned oral thiopurine on days 57-105 and oral methotrexate on days 57 64 71 78 85 92 99 and 106
Delayed intensification I Patients receive oral dexamethasone twice a day on days 113-119 and 127-133 plus vincristine IV and daunorubicin IV over 6 hours on days 113 120 and 127 Patients also receive asparaginase IM three days a week for 6 doses beginning on day 114 or 115 and methotrexate IT on day 113 Cyclophosphamide IV over 30 minutes is administered on day 141 Patients also receive oral thioguanine on days 141-154 cytarabine IV or subcutaneously SC twice a day on days 142-145 and 149-152 and methotrexate IT on days 141 and 148
Interim maintenance II Patients receive the assigned oral steroid twice a day on days 162-166 and 190-194 and vincristine IV on days 162 and 190 Patients also receive the assigned oral thiopurine on days 162-210 and oral methotrexate on days 162 169 176 183 190 197 204 and 211
Delayed intensification II Patients receive oral dexamethasone on days 218-224 and 239-245 vincristine IV and doxorubicin IV over 6 hours on days 218 225 and 232 and methotrexate IT on day 218 Asparaginase IM is administered three days a week for 6 doses beginning on day 219 or 220 Patients then receive cyclophosphamide IV over 30 minutes on day 246 oral thioguanine on days 246-259 cytarabine IV or SC on days 247-250 and 254-257 and methotrexate IT on days 246 and 253
Maintenance Treatment is given as a 12-week course for 6 courses girls or 11 courses boys Patients receive the assigned oral steroid twice a day on days 1-5 29-33 and 57-61 of each course vincristine IV on days 1 29 and 57 of each course and the assigned oral thiopurine daily during each course Methotrexate IT is administered to girls on day 1 of each course and on day 84 of course 6 while boys receive 1 dose on day 1 of course 11 Patients also receive oral methotrexate on days 8 15 22 29 36 43 50 57 64 71 and 78 of each course
Regimen B intermediate-risk patients
Remission induction Patients receive the assigned oral steroid vincristine and asparaginase as in regimen A remission induction Patients also receive daunorubicin IV over 6 hours on days 1 8 15 and 22 cytarabine IT on day 1 and methotrexate IT on day 8
If bone marrow is M3 at day 8 or M2 at day 29 therapy continues on regimen C Otherwise patient continues on regimen B
Consolidation The assigned steroid is tapered over days 29-35 Patients also receive cyclophosphamide IV over 30 minutes on days 29 and 43 cytarabine IV or SC on days 30-33 37-40 44-47 and 51-54 oral mercaptopurine on days 29-56 and methotrexate IT on days 29 36 43 and 50
Patients with M1 or M2 bone marrow on day 64 proceed to interim maintenance I
Interim maintenance I Patients receive the assigned steroid vincristine the assigned thiopurine and oral methotrexate as in regimen A Patients also receive methotrexate IT on days 64 and 92
Delayed intensification I Patients receive oral dexamethasone on days 120-126 and 134-140 plus vincristine IV and doxorubicin IV over 6 hours on days 120 127 and 134 Patients also receive asparaginase IM three days a week for 6 doses beginning on day 121 or 122 and methotrexate IT on day 120 Patients then receive cyclophosphamide IV over 30 minutes on day 148 oral thioguanine on days 148-161 cytarabine IV or SC on days 149-152 and 156-159 and methotrexate IT on days 148 and 155
Interim maintenance II Patients receive the assigned oral steroid twice a day on days 169-173 and 197-201 vincristine IV on days 169 and 197 the assigned oral thiopurine on days 169-217 oral methotrexate on days 176 183 190 197 204 and 211 and methotrexate IT on days 169 and 197
Delayed intensification II Patients receive oral dexamethasone on days 225-231 and 239-245 vincristine IV and doxorubicin IV over 6 hours on days 225 232 and 239 and methotrexate IT on day 225 Asparaginase IM is administered three days a week for 6 doses beginning on day 226 or 227 Patients then receive cyclophosphamide IV over 30 minutes on day 253 oral thioguanine on days 253-266 cytarabine IV or SC on days 253-256 and 260-263 and methotrexate IT on days 253 and 260
Maintenance Treatment is administered as in regimen A
Regimen C Slow early response to regimen A or B OR high-risk patients
Remission induction for patients switching from regimen A Patients continue assigned oral steroid for a total of 35 days Patients also receive vincristine IV on days 15 22 and 29 and daunorubicin IV over 6 hours on days 15 and 22 Asparaginase IM is administered 3 days a week for 6 doses Patients receive methotrexate IT on day 29 patients with CNS disease also receive doses on days 15 and 22
Remission induction for patients switching from regimen B Patients continue assigned oral steroid for a total of 35 days Patients also receive vincristine IV and daunorubicin IV over 6 hours on days 8 15 and 22 Asparaginase IM continues three days a week for up to 6 doses Patients also receive methotrexate IT on day 29 patients with CNS disease also receive doses on days 14 and 21
Consolidation Patients receive cyclophosphamide IV over 30 minutes on days 36 and 64 cytarabine IV or SC on days 37-40 44-47 65-68 and 72-75 oral mercaptopurine on days 36-49 and 64-77 vincristine IV on days 50 57 78 and 85 pegaspargase IM on days 50 and 78 and methotrexate IT on days 36 43 50 and 57
Interim maintenance I Patients receive vincristine IV and methotrexate IV on days 99 109 119 129 and 139 Pegaspargase IM is administered on days 100 and 110 and methotrexate IT is administered on days 99 and 129 patients with CNS disease do not receive the dose on day 129
Patients with M1 or M2 bone marrow proceed to delayed intensification I
Delayed intensification I
Reinduction Patients receive vincristine IV and doxorubicin IV over 6 hours on days 162 169 and 176 oral dexamethasone twice a day on days 162-168 and 176-82 methotrexate IT on day 162 and pegaspargase IM on day 165
Reconsolidation Patients receive cyclophosphamide IV over 30 minutes on day 190 oral thioguanine on days 190-203 cytarabine IV or SC on days 191-194 and 197-200 vincristine IV on days 204 and 211 and pegaspargase IM on day 204 Methotrexate IT is administered on days 190 and 197 patients with CNS disease do not receive the dose on day 197
Interim maintenance II Patients receive vincristine IV and methotrexate IV on days 218 228 238 248 and 258 Pegaspargase IM is administered on days 219 and 239 Patients also receive methotrexate IT on days 218 and 248 patients with CNS disease do not receive the dose on day 248
Delayed intensification II
Reinduction Patients receive vincristine IV and doxorubicin IV over 6 hours on days 274 281 and 288 oral dexamethasone twice a day on days 274-280 and 288-294 methotrexate IT on day 274 and pegaspargase IM on day 277
Reconsolidation Patients receive cyclophosphamide IV over 30 minutes on day 302 oral thioguanine on days 302-315 cytarabine IV or SC on days 303-306 and 309-312 and vincristine IV on days 316 and 323
Maintenance Treatment is administered as in regimen A
PROJECTED ACCRUAL Approximately 1800 patients will be accrued for this study within 6 years
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EU-97032 | None | None | None |
| MRC-LEUK-ALL97 | None | None | None |